查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1834078

冠狀動脈疾病治療設備市場（按設備類型、治療類型、方法和最終用戶分類）—2025-2032 年全球預測

Coronary Artery Disease Treatment Devices Market by Device Type, Treatment Type, Approach, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年冠狀動脈疾病治療設備市場將成長至 72.6 億美元，複合年成長率為 5.92%。

主要市場統計數據
基準年2024年 45.8億美元
預計2025年 48.4億美元
預測年份：2032年 72.6億美元
複合年成長率（%） 5.92%

對重塑冠狀動脈疾病治療方法的臨床複雜性、設備創新途徑和醫療保健重點的權威概述

在技​​術創新、手術偏好變化以及醫療服務模式轉變的共同影響下，冠狀動脈疾病治療設備的臨床和商業性格局正在迅速演變。患者的病症日益複雜，包括高度鈣化病變、慢性完全阻塞和合併症，需要細緻入微的治療方法。同時，臨床醫生正在將更高解析度的血管內影像和生理工具整合到日常決策中，以提高手術準確性和長期療效。

在這樣的臨床背景下，器械開發商和醫療保健系統正在平衡多項重要因素：提高急性手術成功率、減少再次手術，以及展現符合付款方期望的持續患者獲益。器械設計的進步，例如用於矯正鈣化斑塊的精密動脈粥狀硬化斑塊切除術樣硬化切除術和用於抑制血管再阻塞的增強型藥物輸送球囊技術，與有利於微創入路和縮短住院時間的手術流程轉變相輔相成。應對這些動態變化需要一種跨職能策略，將臨床證據產生、監管途徑、報銷定位和供應鏈彈性連結起來。

本執行摘要總結了目前影響冠狀動脈器械的促進因素，並指出了可能影響產品採用、臨床實踐和商業策略的結構性變化。本分析將臨床創新置於衛生系統優先事項和營運現實的背景下，為高階主管和臨床領導者提供結構性基礎，使其能夠根據不斷變化的未滿足需求調整投資。

影像學、生理學、斑塊修飾和手術入路趨勢如何融合，重新定義冠狀動脈治療的治療基準和設備採用

冠狀動脈介入治療的構思、設計和實施方式正在發生數次變革。這些變革正在加速影像學、生理學和治療設備功能的融合。首先，血管內影像學和生理學評估正從可選的輔助手段轉變為病例規劃和最佳化的核心組成部分。血管內超音波和光同調斷層掃瞄的廣泛應用，以及基於血流儲備分數的決策，正在提高病灶層面的診斷準確性，並使更有針對性的設備選擇和置入策略成為可能。

其次，複雜病變（尤其是鈣化性冠狀動脈疾病）的增多，推動了對專用斑塊修復工具的需求。包括雷射、軌道和旋轉在內的動脈粥狀硬化斑塊切除術技術正在不斷改進，以提高安全性並整合輔助性治療。同時，藥物釋放型支架技術和藥物塗層球囊也在不斷發展，其聚合物和藥物配方也在不斷改進，旨在延長球囊的耐用性，同時最大限度地減少晚期不利事件。這些設備的進步正在鼓勵在單一病例中結合多種互補技術的混合手術策略。

第三，為了減少血管併發症並提高病患吞吐量，許多醫療中心正在轉向使用橈動脈路徑進行手術。這種轉變正在改變與輪廓、輸送能力和扭矩控制相關的器械設計考慮。最後，醫療保健領域的數位化和數據主導轉型，包括手術分析和真實世界證據生成，使製造商能夠透過記錄長期療效、經濟影響和生活品質改善來展示超越手術成功的價值。競爭性基準化分析正在重塑競爭動態，並為臨床證據和器械性能建立新的基準。

評估美國關稅調整對冠狀動脈設備供應鏈和定價策略的累積營運、採購和監管影響

2025年美國關稅和貿易政策的實施將對器械採購、定價策略和供應鏈架構產生累積影響，促使產業相關人員重新評估其營運模式。向受影響國家和地區供應零件和成品的製造商面臨利潤壓力，因此他們加快了供應商多元化和探索近岸外包選項的步伐。這些調整強調了雙重採購策略、替代供應商的資格認定以及庫存最佳化，以保持臨床供應的連續性。

同時，採購部門和衛生系統重組了合約框架，以應對潛在的成本波動。透過協商簽訂長期合約和價格保護條款，以降低風險敞口，同時一些買家採取了更積極的庫存管理和需求預測，以減少採購摩擦。關稅也更加重視製造業的韌性，鼓勵對美洲區域製造能力和製造外包夥伴關係的投資。

產品重新貼標、原產國文件變更以及物流路線變更增加了行政管理的複雜性以及監管和合規負擔。為了因應這種情況，企業利用跨職能團隊，結合監管、品質和供應鏈專業知識，加速變更管理並維持監管合規性。從策略上講，關稅的累積影響迫使許多公司優先考慮產品設計和籌資策略，以最大限度地減少受關稅影響的成分，加快本地資格確認工作，並利用臨床療效證據在受限的報銷環境中保護定價權。

深入的細分分析將設備模式、治療途徑、獲取策略和醫療保健環境與採用機會和產品定位聯繫起來

細緻的細分鏡頭揭示了跨裝置類型、治療方式、程序方法和最終用戶設定的不同機會區和操作考慮因素。按類型對設備進行分類需要分析動脈粥狀硬化斑塊切除術系統，包括雷射、軌道和旋轉迭代。球囊導管技術包括切割、藥物塗層和標準設計，藥物塗層球囊與支架內血管再阻塞和小血管疾病的關係越來越密切。導管導引線，根據病變複雜性和輸送需求發揮不同的作用。血管內成像系統包括分數流量儲備平台、血管內超音波和光同調斷層掃瞄，每個系統都提供獨特的診斷解析度，以指導設備選擇和部署技術。支架平台包括裸金屬結構、生物可吸收支架和藥物釋放型設計，急性支架、長期血管癒合和設備壽命之間的權衡決定了臨床醫生的偏好。

在考慮治療類型時，冠狀動脈繞道手術手術仍是某些解剖和多支血管病變的必要選擇，非體外循環和體外循環策略仍保留一定的臨床原理。經皮介入治療，無論是單獨球囊血管成形術或聯合置入術，其範圍都在隨著輔助技術和操作的改進而不斷擴大。隨著多學科心臟團隊評估和病變水平診斷的提高，手術和經皮治療之間的選擇也越來越個人化。

經股動脈或經橈動脈入路的選擇會影響器械設計和手術物流，因為橈動脈優先的實踐優先考慮低調、易於輸送的器械，而股動脈入路可能需要使用笨重的輔助器具。門診手術中心、心臟中心和醫院的終端使用者細分反映了不同的手術複雜性、資源密集度和報銷考量，從而形成了差異化的採用路徑。每個細分領域都需要量身定做的證據產生、定價策略和服務模式，以最佳化在異質臨床環境中的採用。

美洲、歐洲、中東和非洲以及亞太地區的區域動態將影響各地區的監管途徑、採用重點和商業化策略

美洲、歐洲、中東和非洲以及亞太地區的區域動態創造了獨特的需求促進因素和業務需求，塑造了監管格局、報銷格局和臨床實踐模式。在美洲，程序創新通常與注重實際結果和成本效益的綜合支付系統和大型醫院網路交叉。這種環境獎勵商投資於強力的上市後證據和醫療保健提供者教育計劃，以將設備優勢轉化為可衡量的臨床和經濟價值。

歐洲、中東和非洲地區監管和報銷框架的差異性使得制定區域性打入市場策略成為必要。西方市場通常需要嚴格的醫療技術評估和針對特定國家的臨床證據，而該地區的新興市場可能更注重成本控制和可擴展的解決方案。在該地區發展的製造商必須根據不同國家醫療保健體系的期望，量身定做定價、臨床支援和監管提交方案。

亞太地區擁有龐大的手術市場和快速發展的臨床能力，多個國家對介入性心臟病學基礎設施進行了大規模投資。本地製造和夥伴關係關係尤其重要，因為區域供應鏈整合和監管協作將加速該領域的應用。各地區人口結構變化——人口老化和心血管疾病負擔的增加——正在推動持續的臨床需求，但區域報銷、醫護人員培訓和衛生系統的優先事項將決定設備應用的速度和性質。

產品整合、臨床證據、供應鏈穩健性和商業化專業知識如何定義冠狀動脈設備製造商的競爭優勢

活躍於冠狀動脈器械研發領域的公司之間的競爭動態取決於技術領導力、臨床證據生成、生產規模和市場敏銳度的整合。領先的公司優先考慮整合治療設備和診斷平台的整合產品組合，從而提供捆綁式流程解決方案，以支援更優的病例選擇和最佳化。隨著醫療體系越來越重視長期療效和經濟價值的展現，對臨床試驗、註冊和上市後監測的投資將持續成為差異化因素。

策略夥伴關係、授權協議和選擇性收購是獲取互補技術、擴大地域覆蓋範圍或加速進入新醫療程序利基市場的常見途徑。供應鏈彈性和監管敏捷性是管理的首要任務，企業透過製造外包網路和區域生產能力來建立冗餘。在臨床營運、證據產生和報銷專業知識方面的人才投資對於將設備性能轉化為採用和有利的採購結果同樣重要。

產品差異化日益聚焦於可交付性、特異性病變的性能以及輔助診斷相容性。提供臨床醫生培訓計劃、程序支援和強巨量資料收集能力的公司，將有望加速技術應用並獲得長期臨床認可。隨著競爭格局的成熟，那些能夠將技術創新與切實可行的商業化模式相結合，並反映臨床醫生工作流程和付款人期望的公司將成為贏家。

領導者需要採取實際的策略措施，協調產品創新、供應鏈彈性和以證據主導的商業化，以實現永續成長

為了獲取持續價值，產業領導者應優先制定產品組合策略，強調具有臨床意義的差異化、監管前瞻性和供應鏈適應性。首先，選擇性地投資於能夠解決臨床影響缺口（例如鈣化病變、小血管疾病和血管再阻塞）的設備改進，同時確保設計改進能夠增強橈動脈入路的可及性。能夠產生隨機證據和真實世界註冊數據的合作臨床計畫將強化對臨床醫生和付款人的價值提案，並支持更廣泛的應用和報銷協調。

其次，我們建構了一個富有彈性的採購架構，透過審核多家供應商、探索區域製造夥伴關係以及納入關稅感知採購條款來緩解政策引發的成本衝擊。跨職能團隊負責快速變更管理流程，在確保合規性的同時加快供應商入職。第三，我們將產品發布與整合血管內成像和生理學工具的全面臨床醫生教育和程序培訓相結合，從而縮短學習曲線並改善程序結果。一個能夠捕捉程序指標和患者結果的數位平台可以支持迭代改進並強化上市後證據。

最後，在適當的情況下，採用靈活的商業模式，例如捆綁銷售和與結果掛鉤的契約，使定價與已證實的結果和系統層面的價值保持一致。與醫療系統合作試行整合護理路徑可以提高營運效率，並為更廣泛的應用提供案例研究。這些行動協同實施，可以增強韌性，並在日益以結果主導的環境中創造具有競爭力的差異化優勢。

嚴格的多模態調查方法，整合臨床證據、相關人員訪談、監管見解和供應鏈分析，以得出可靠的結論

本分析整合了旨在反映臨床實踐、監管環境和供應鏈現狀的多模態調查方法的成果。該調查方法結合了同行評審臨床文獻、手術登記和器械標籤的全面回顧，以確定器械的性能特徵和臨床應用模式。此外，我們也對介入性心臟病專家、醫院採購負責人、監管專家和器械開發主管進行了結構化訪談，以了解該領域對應用促進因素、未滿足需求和營運限制的觀點。

作為補充資訊來源，我們審查了監管備案文件、標準指南和已發布的衛生技術評估，以了解不同司法管轄區的證據要求。我們的供應鏈分析整合了進出口數據趨勢、已發布的貿易和關稅政策更新以及委託製造的匿名洞察，以繪製採購和製造風險圖。我們進行了專利挖掘和研發管線追蹤，以識別新興技術和研發重點領域。

在整個研究過程中，我們對研究結果進行了跨資訊來源三角檢驗，以確保研究結果的穩健性，並最大限度地減少單一資訊來源的偏差。證據綜合強調了臨床相關性、監管效度和商業性適用性，為本文提出的見解和建議奠定了均衡的基礎。

簡明綜合臨床、營運和策略促進因素，確定哪些設備策略將帶來持久的臨床和商業性價值

冠狀動脈疾病治療設備的發展軌跡取決於技術的成熟度、不斷演進的診療流程以及對已證實的臨床和經濟價值予以獎勵的環境。血管內影像和生理學的進步使得更精準的病變層面決策成為可能，而標靶治療設備，從先進的動脈粥樣硬化斑塊切除系統到藥物輸送球囊和現代支架平台，則能夠應對日益複雜的臨床表現。這些臨床促進因素與可及性趨勢、付款人審查和供應鏈壓力等營運現實因素相互交織，共同營造出有利於整合解決方案和實證商業化策略的氛圍。

那些將設備設計與臨床醫生工作流程相結合、投資於以結果為導向的證據產生並建立供應鏈彈性的組織，最有可能實現持久的採用。由於不同地區的證據要求和報銷動態各不相同，監管靈活性和針對特定區域的市場策略仍然至關重要。最終，持續的成功取決於能否將技術能力轉化為明確的臨床效益和系統級價值。

本摘要中的建議提供了藍圖，旨在協調研發、監管、供應鏈和商業性行動，以滿足不斷變化的臨床醫生期望和醫療保健系統需求。企業主管和臨床領導者可以參考這些見解，確定優先投資方向，從而顯著改善患者照護和組織成果。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用生物可吸收血管支架減少長期併發症
  • 實施人工智慧引導的成像演算法，用於即時病變評估
  • 開發無聚合物藥物塗層球囊用於治療血管再阻塞
  • 機器人 PCI 平台的發展提高了手術精度並減少了透視輻射暴露
  • 用於術前規劃的患者專用 3D 列印冠狀動脈模型的興起
  • 抗血栓和抗增生藥物聯合治療支架的出現
  • 整合穿戴式心臟監測設備用於 PCI 後患者監測
  • 擴展微導管技術用於複雜分叉病變和慢性完全閉塞的干涉
  • 使用光學同調斷層掃描與血管內超音波融合來詳細表徵斑塊
  • 可生物分解聚合物塗層的進展可最大程度減少支架置入後的發炎反應

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 冠狀動脈疾病治療設備市場（依設備類型）

  • 動脈粥狀硬化斑塊切除裝置
    • 雷射動脈粥狀硬化斑塊切除術
    • 眼眶斑塊動脈粥狀硬化斑塊切除術
    • 旋磨動脈粥狀硬化斑塊切除術
  • 球囊導管
    • 切割球囊導管
    • 藥物塗層球囊導管
    • 標準球囊導管
  • 導管導引線
    • 聚合物護套
    • PTFE塗層
    • 未治療
  • 血管內成像系統
    • 血流儲備分數
    • 血管內超音波
    • 光學同調斷層掃描
  • 支架
    • 裸金屬支架
    • 生物可吸收支架
    • 藥物釋放型支架

9. 冠狀動脈疾病治療設備市場（依治療類型）

  • 冠狀動脈繞道手術手術
    • 非泵浦
    • 泵浦上
  • 經皮冠狀動脈介入治療
    • 球囊血管成形術
    • 支架置入術

10. 冠狀動脈疾病治療設備市場（依方法）

  • 經股動脈路徑
  • 經橈動脈入路

第 11 章：冠狀動脈疾病治療設備市場（依最終使用者）

  • 門診手術中心
  • 心臟中心
  • 醫院

12. 冠狀動脈疾病治療設備市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章：冠狀動脈疾病治療設備市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 冠狀動脈疾病治療設備市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • Biotronik SE & Co. KG
    • Lepu Medical Technology（Beijing）Co., Ltd.
    • Meril Life Sciences Pvt. Ltd.
    • OrbusNeich Medical Company Limited
    • MicroPort Scientific Corporation
    • Cardinal Health, Inc.
Product Code: MRR-4311CE1A33CA

The Coronary Artery Disease Treatment Devices Market is projected to grow by USD 7.26 billion at a CAGR of 5.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.58 billion
Estimated Year [2025] USD 4.84 billion
Forecast Year [2032] USD 7.26 billion
CAGR (%) 5.92%

An authoritative overview of clinical complexities, device innovation pathways, and healthcare priorities reshaping coronary artery disease treatment approaches

The clinical and commercial landscape for coronary artery disease treatment devices is evolving rapidly under the combined influence of technological innovation, shifting procedural preferences, and changing healthcare delivery models. Patients present with increasingly complex anatomies including heavily calcified lesions, chronic total occlusions, and comorbidities that demand nuanced therapeutic approaches. At the same time, clinicians are integrating higher-resolution intravascular imaging and physiology tools into routine decision-making to improve procedural precision and long-term outcomes.

Against this clinical backdrop, device developers and healthcare systems are balancing several imperatives: improving acute procedural success, reducing repeat interventions, and demonstrating durable patient benefit that aligns with payor expectations. Advances in device design, such as refined atherectomy modalities for calcified plaque modification and enhanced drug-delivery balloon technologies to limit restenosis, are complemented by procedural shifts favoring minimally invasive access and shorter hospital stays. These dynamics necessitate cross-functional strategies that link clinical evidence generation, regulatory pathways, reimbursement positioning, and supply chain resilience.

This executive summary synthesizes current drivers affecting coronary devices and highlights structural shifts likely to influence product adoption, clinical practice, and commercial strategy. The analysis places clinical innovation in the context of health system priorities and operational realities, offering a structured foundation for executives and clinical leaders to align investments with evolving unmet needs.

How imaging, physiology, plaque modification, and procedural access trends are converging to redefine therapeutic benchmarks and device adoption in coronary care

Several transformative shifts are reshaping how coronary interventions are conceived, designed, and delivered, and these shifts are accelerating the convergence of imaging, physiology, and therapeutic device capabilities. First, intravascular imaging and physiologic assessment are moving from optional adjuncts to central components of case planning and optimization. The broader adoption of intravascular ultrasound and optical coherence tomography, alongside fractional flow reserve-guided decision-making, has increased lesion-level diagnostic precision and enabled more targeted device selection and deployment strategies.

Second, the growth in complex lesion subsets, particularly calcified coronary disease, has strengthened demand for specialized plaque-modification tools. Atherectomy technologies, including laser, orbital, and rotational modalities, are being refined to improve safety profiles and integration with adjunctive therapies. Concurrently, drug-eluting stent technologies and drug-coated balloons continue to evolve with refined polymer and drug formulations intended to extend durability while minimizing late adverse events. These converging device advancements are prompting hybrid procedural strategies where multiple complementary technologies are deployed within a single case.

Third, procedural access preferences are shifting toward radial approaches in many centers, reducing vascular complications and supporting faster patient throughput. This change is altering device design considerations related to profile, deliverability, and torque control. Finally, the digital and data-driven transformation in healthcare, including procedural analytics and real-world evidence generation, is enabling manufacturers to demonstrate value beyond immediate procedural success by documenting longitudinal outcomes, economic impact, and quality-of-life improvements. Collectively, these shifts are reconfiguring competitive dynamics and establishing new benchmarks for clinical evidence and device performance.

Assessing the cumulative operational, procurement, and regulatory consequences of United States tariff adjustments on coronary device supply chains and pricing strategies

The introduction of tariffs and trade policy changes in the United States in 2025 has exerted a cumulative influence across device sourcing, pricing strategies, and supply chain architecture, prompting industry actors to reassess operational models. Manufacturers with significant component or finished-goods exposure to affected jurisdictions experienced margin pressure, which in turn accelerated initiatives to diversify suppliers and examine nearshoring alternatives. These adaptations emphasized dual-sourcing strategies, qualification of alternative suppliers, and inventory optimization to sustain clinical supply continuity.

In parallel, procurement departments and health systems revisited contracting frameworks to account for potential cost volatility. Longer-term agreements and price-protection clauses have been negotiated to mitigate exposure, while some purchasers adopted more active inventory management and demand forecasting to reduce procurement friction. The tariffs also intensified focus on manufacturing footprint resilience, encouraging investment in regional manufacturing capacity and contract manufacturing partnerships in the Americas.

Regulatory and compliance burdens increased as well, since product relabeling, changes in country-of-origin documentation, and logistics re-routing added administrative complexity. Companies responded by strengthening cross-functional teams combining regulatory affairs, quality, and supply chain expertise to accelerate change controls and maintain regulatory compliance. Strategically, the cumulative impact of tariffs compelled many players to prioritize product designs and sourcing strategies that minimize tariff-exposed components, accelerate local qualification efforts, and use evidence of clinical effectiveness to defend pricing power within constrained reimbursement environments.

Insightful segmentation analysis linking device modalities, treatment pathways, access strategies, and care settings to adoption levers and product positioning

A nuanced segmentation lens reveals distinct opportunity zones and operational considerations across device type, treatment modality, procedural approach, and end-user setting. When devices are categorized by type, the analysis must account for atherectomy systems-which include laser, orbital, and rotational iterations-each optimized for different plaque morphologies and clinical scenarios. Balloon catheter technologies span cutting, drug-coated, and standard designs, with drug-coated balloons growing in relevance for in-stent restenosis and small-vessel disease. Guidewire variants such as polymer-jacketed, PTFE-coated, and untreated options continue to serve differentiated procedural roles depending on lesion complexity and deliverability needs. Intravascular imaging systems encompass fractional flow reserve platforms, intravascular ultrasound, and optical coherence tomography, each contributing unique diagnostic resolution that informs device selection and deployment technique. Stent platforms include bare metal constructs, bioresorbable scaffolds, and drug-eluting designs, with trade-offs in acute scaffolding, long-term vessel healing, and device longevity shaping clinician preference.

Examining treatment types reveals that coronary artery bypass grafting remains an essential option for specific anatomic and multivessel presentations, with off-pump and on-pump strategies retaining particular clinical rationales. Percutaneous coronary intervention continues to expand in scope through adjunctive technologies and procedural refinements, whether performed with balloon angioplasty alone or combined with stenting. The choice between surgical and percutaneous pathways is increasingly individualized through multidisciplinary heart team assessment and enhanced lesion-level diagnostics.

Approach selection between transfemoral and transradial access frames device design and procedural logistics, since radial-first practices prioritize low-profile, highly deliverable devices, while femoral access may accommodate bulkier adjunctive tools. End-user segmentation across ambulatory surgical centers, cardiac centers, and hospitals reflects varying procedural complexity, resource intensity, and reimbursement considerations, creating differentiated adoption pathways. Each segmentation axis requires tailored evidence generation, pricing strategies, and service models to optimize uptake across heterogeneous clinical settings.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory pathways, adoption priorities, and localized commercialization strategies

Regional dynamics create differentiated demand drivers and operational imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific, shaping regulatory pathways, reimbursement landscapes, and clinical practice patterns. In the Americas, procedural innovation often intersects with consolidated payer systems and large hospital networks that emphasize real-world outcomes and cost-effectiveness; there is strong appetite for demonstrable improvements in procedural efficiency and reduction in repeat interventions. This context incentivizes manufacturers to invest in robust post-market evidence and provider education programs that translate device advantages into measurable clinical and economic value.

In Europe, the Middle East and Africa, heterogeneous regulatory and reimbursement frameworks necessitate localized market-entry strategies. Western European markets frequently require rigorous health technology assessments and country-specific clinical evidence, while emerging markets in the broader region may prioritize cost containment and scalable solutions that support expanding procedural capacity. Manufacturers navigating this geography must align pricing, clinical support, and regulatory submissions to the expectations of diverse national health systems.

The Asia-Pacific region presents a combination of high-volume procedural markets and rapidly advancing clinical capabilities, with several countries investing significantly in interventional cardiology infrastructure. Local manufacturing and partnerships are particularly influential here, as regional supply chain integration and regulatory alignment can accelerate adoption. Across all regions, demographic shifts toward aging populations and rising cardiovascular disease burden drive sustained clinical demand, but regional reimbursement, provider training, and health system priorities will determine the pace and nature of device uptake.

How product integration, clinical evidence, supply chain robustness, and commercialization expertise define competitive advantage among coronary device manufacturers

Competitive dynamics among companies active in coronary device development are defined by a blend of technology leadership, clinical evidence generation, manufacturing scale, and go-to-market sophistication. Leading firms prioritize integrated portfolios that pair therapeutic devices with diagnostic platforms, enabling bundled procedural solutions that support better case selection and optimization. Investment in clinical trials, registries, and post-market surveillance continues to be a differentiator, as health systems increasingly reward demonstrable long-term outcomes and economic value.

Strategic partnerships, licensing agreements, and selective acquisitions are common tools to access complementary technologies, expand geographic reach, or accelerate entry into emerging procedural niches. Supply chain resilience and regulatory agility are prominent operational priorities, with companies enhancing redundancy through contract manufacturing networks and regional production capacity. Talent investment in clinical affairs, evidence generation, and reimbursement expertise is equally important to translate device performance into adoption and favorable procurement outcomes.

Product differentiation increasingly centers on deliverability, lesion-specific performance, and adjunctive diagnostic compatibility. Companies that offer clinician training programs, procedural support, and robust data capture capabilities are better positioned to shorten adoption curves and build long-term clinical endorsement. As the competitive landscape matures, winners will be those who can integrate technical innovation with pragmatic commercialization models that reflect clinician workflows and payer expectations.

Practical strategic imperatives for leaders to align product innovation, supply chain resilience, and evidence-driven commercialization for sustainable growth

Industry leaders should prioritize a portfolio strategy that emphasizes clinically meaningful differentiation, regulatory foresight, and supply chain adaptability to capture sustained value. First, invest selectively in device improvements that address high-impact clinical gaps such as calcified lesions, small-vessel disease, and restenosis, while ensuring that design changes enhance deliverability for radial approaches. Coordinated clinical programs that generate both randomized evidence and real-world registry data will strengthen value propositions with clinicians and payers, supporting broader adoption and reimbursement alignment.

Second, build resilient sourcing architectures by qualifying multiple suppliers, exploring regional manufacturing partnerships, and embedding tariff-aware procurement clauses to mitigate policy-driven cost shocks. Cross-functional teams should own rapid change-control processes to accelerate supplier onboarding while maintaining regulatory compliance. Third, couple product launches with comprehensive clinician education and procedural training that integrate intravascular imaging and physiology tools, thereby shortening learning curves and improving procedural outcomes. Digital platforms that capture procedural metrics and patient outcomes can support iterative improvement and strengthen post-market evidence.

Finally, adopt flexible commercial models that align pricing with demonstrated outcomes and system-level value, including bundled agreements and outcome-linked contracts where appropriate. Collaboration with health systems to pilot integrated care pathways can surface operational efficiencies and provide reference cases for wider adoption. These actions, executed in parallel, will enhance resilience and create defensible differentiation in an increasingly outcome-driven environment.

A rigorous, multi-modal research methodology integrating clinical evidence, stakeholder interviews, regulatory insights, and supply chain analysis to ensure robust conclusions

This analysis synthesizes insights drawn from a multi-modal research approach designed to reflect clinical practice, regulatory context, and supply chain realities. The methodology combined a comprehensive review of peer-reviewed clinical literature, procedural registries, and device labeling to establish device performance characteristics and clinical application patterns. In addition, structured interviews were conducted with interventional cardiologists, hospital procurement leaders, regulatory specialists, and device development executives to capture frontline perspectives on adoption drivers, unmet needs, and operational constraints.

Supplementary sources included a review of regulatory filings, standards guidance, and published health technology assessments to understand evidence expectations across jurisdictions. Supply chain analysis incorporated import-export data trends, published policy updates related to trade and tariffs, and anonymized insights from contract manufacturers to map procurement and manufacturing risk. Patent landscaping and pipeline tracking were used to identify emerging technologies and R&D focus areas.

Throughout the research process, findings were triangulated across sources to ensure robustness and to minimize single-source bias. Evidence synthesis emphasized clinical relevance, regulatory plausibility, and commercial applicability, providing a balanced foundation for the insights and recommendations presented herein.

A concise synthesis of clinical, operational, and strategic drivers that will determine which device strategies deliver enduring clinical and commercial value

The trajectory of coronary artery disease treatment devices is defined by technological refinement, procedural evolution, and an environment that rewards demonstrable clinical and economic value. Advances in intravascular imaging and physiology are enabling more precise, lesion-level decision-making, while targeted therapeutic devices-ranging from advanced atherectomy systems to drug-delivery balloons and modern stent platforms-are addressing increasingly complex clinical presentations. These clinical drivers intersect with operational realities such as access trends, payer scrutiny, and supply chain pressures, creating a landscape that favors integrated solutions and evidence-rich commercialization strategies.

Organizations that align device design with clinician workflow, invest in outcome-focused evidence generation, and build supply chain resilience will be best positioned to capture durable adoption. Regulatory agility and region-specific market approaches remain essential as jurisdictions vary in evidence requirements and reimbursement dynamics. Ultimately, sustained success will hinge on the ability to translate technical performance into clear clinical benefit and system-level value, enabling providers and payers to justify adoption amid competing budgetary and operational priorities.

The recommendations in this summary provide a roadmap for aligning R&D, regulatory, supply chain, and commercial actions to meet evolving clinician expectations and health system demands. Executives and clinical leaders can leverage these insights to prioritize investments that yield meaningful improvements in patient care and organizational outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of bioresorbable vascular scaffolds for reduced long-term complications
  • 5.2. Implementation of AI-guided imaging algorithms for real-time lesion assessment
  • 5.3. Development of polymer-free drug-coated balloons for in-stent restenosis management
  • 5.4. Growth of robotic PCI platforms for enhanced procedural precision and reduced fluoroscopy exposure
  • 5.5. Rise of patient-specific 3D printed coronary artery models for pre-operative planning
  • 5.6. Emergence of dual therapy stents combining antithrombotic and antiproliferative agents
  • 5.7. Integration of wearable cardiac monitoring devices for post-PCI patient surveillance
  • 5.8. Expansion of microcatheter technologies for complex bifurcation and chronic total occlusion interventions
  • 5.9. Use of optical coherence tomography fused with intravascular ultrasound for detailed plaque characterization
  • 5.10. Advancements in biodegradable polymer coatings to minimize inflammatory response after stent implantation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coronary Artery Disease Treatment Devices Market, by Device Type

  • 8.1. Atherectomy Device
    • 8.1.1. Laser Atherectomy
    • 8.1.2. Orbital Atherectomy
    • 8.1.3. Rotational Atherectomy
  • 8.2. Balloon Catheter
    • 8.2.1. Cutting Balloon Catheter
    • 8.2.2. Drug-Coated Balloon Catheter
    • 8.2.3. Standard Balloon Catheter
  • 8.3. Guidewire
    • 8.3.1. Polymer-Jacketed
    • 8.3.2. PTFE-Coated
    • 8.3.3. Untreated
  • 8.4. Intravascular Imaging System
    • 8.4.1. Fractional Flow Reserve
    • 8.4.2. Intravascular Ultrasound
    • 8.4.3. Optical Coherence Tomography
  • 8.5. Stent
    • 8.5.1. Bare Metal Stent
    • 8.5.2. Bioresorbable Scaffold
    • 8.5.3. Drug Eluting Stent

9. Coronary Artery Disease Treatment Devices Market, by Treatment Type

  • 9.1. Coronary Artery Bypass Grafting
    • 9.1.1. Off Pump
    • 9.1.2. On Pump
  • 9.2. Percutaneous Coronary Intervention
    • 9.2.1. With Balloon Angioplasty
    • 9.2.2. With Stenting

10. Coronary Artery Disease Treatment Devices Market, by Approach

  • 10.1. Transfemoral Approach
  • 10.2. Transradial Approach

11. Coronary Artery Disease Treatment Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals

12. Coronary Artery Disease Treatment Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Coronary Artery Disease Treatment Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Coronary Artery Disease Treatment Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Boston Scientific Corporation
    • 15.3.3. Medtronic plc
    • 15.3.4. Terumo Corporation
    • 15.3.5. Biotronik SE & Co. KG
    • 15.3.6. Lepu Medical Technology (Beijing) Co., Ltd.
    • 15.3.7. Meril Life Sciences Pvt. Ltd.
    • 15.3.8. OrbusNeich Medical Company Limited
    • 15.3.9. MicroPort Scientific Corporation
    • 15.3.10. Cardinal Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CORONARY ARTERY DISEASE TREATME